https://www.optimumcomms.com/wp-content/uploads/2023/02/Sofinnova_Logo_300-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-07-13 07:04:212026-07-13 16:07:14Sofinnova Partners appoints David Evans as Partner
https://www.optimumcomms.com/wp-content/uploads/2023/02/Sofinnova_Logo_300-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-07-13 07:04:212026-07-13 16:07:14Sofinnova Partners appoints David Evans as Partner
No easy answers: European research consortia take on major challenges
Nine new Challenge Programme grants from the Novo Nordisk Foundation…

Hansa Biopharma to host Q2 2026 interim results conference call
Lund, Sweden, 8 July, 2026. Hansa Biopharma, “Hansa” (Nasdaq…

AMSilk and Ajinomoto Foods Europe Expand Partnership to Enable Industrial-Scale Production of Silk Proteins
Neuried/Nesle, 8 July 2026 - AMSilk, a global leader in biotech…

Xeltis makes first commercial implant of aXess™, its vascular access device for hemodialysis
Marks start of European commercial rollout of aXess™, bringing…

Sofinnova Partners announces Myricx Bio agrees to be acquired by Novartis
Sofinnova Partners co-led the seed investment in 2019 and…

Hansa Biopharma participating in Wedbush PacGrow Renal Summit
Lund, Sweden, July 2, 2026. Hansa Biopharma AB, “Hansa”…

Xeltis exceeds 50% enrollment in US Pivotal trial for aXess™, its vascular access device for hemodialysis
US pivotal trial is a multi-center study evaluating a bioabsorbable…

CONNECTA Therapeutics and Centre for Genomic Regulation to Present First-in-Class Program CTH120 for Fragile X Syndrome at FENS Forum 2026
Preclinical data highlight restoration of cognitive, behavioral…

Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA
SERB assumes responsibility for the commercialization of…

R1 Therapeutics establishes world-class Scientific Advisory Board to support advancement of AP306 in Chronic Kidney Disease
Seven internationally recognized nephrology experts join…

Poolbeg Pharma plc – POLB 001 patent granted in South Africa for the treatment or prevention of hypercytokinemia and severe influenza
Patent decision strengthens Poolbeg's intellectual property portfolio
30…

Hansa Biopharma announces ConfIdeS Phase 3 Abstract Selected for ‘What’s Hot, What’s New’ Plenary at ATC 2026
Lund, Sweden, June 24, 2026. Hansa Biopharma AB, “Hansa”…

Novo Nordisk Foundation: New European initiative to accelerate drug discovery for cardiometabolic diseases
The Novo Nordisk Foundation is funding a new pan-European initiative…

Kither Biotech successfully completes Phase 1 clinical trial of KIT2014, a novel inhaled peptide therapy for respiratory diseases
First-in-human Phase 1 study in 56 healthy participants demonstrated…

BIO-Europe unveils renewed vision as the must-attend global biopharma strategy forum
2026 marks BIO-Europe's evolution from partnering-led conference…
We’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
Optimum Strategic Communications’ specialist team has an in-depth understanding of how to communicate complex science to investors and corporate stakeholders. Optimum helps life science companies on their journey as they grow and has been trusted by hundreds of healthcare clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York